MedDataX Logo

Difference in Central Fatigue During Two Ultra-endurance Practices: Running vs. Cycling

NCT ID: NCT04511858

Last Updated: 2021-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-05

Study Completion Date

2021-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mechanisms contributing to muscle fatigue in extreme long-duration exercise bouts are poorly understood. Ultra-endurance exercise is an excellent model for the study of adaptive responses to extreme loads and stress and it is an especially useful model for documenting the origins of central fatigue. This protocol will compare fatigue during and after ultra-endurance exercise bouts that result in moderate lower-limb tissue damage (i.e. cycling) or significant damage (i.e. running). The results of this protocol will allow us to further understanding of the reasons for major central fatigue, i.e. within the central nervous system, in ultra-endurance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ultra-marathon Runners

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

central fatigue peripheral fatigue ultra-endurance exercise corticospinal excitability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Prospective study of physiopathology on subjects specializing in endurance and ultra-endurance: comparing running vs. cycling. Cross-over: each subject will carry out the 2 experimental conditions (running and cycling) according to a randomized order of passage, respecting a wash-out of 2 weeks.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Running endurance

Athletes wiil run for 5 hours in a row.

Group Type EXPERIMENTAL

maximum effort test on a treadmill

Intervention Type OTHER

5 h test on treadmill

Cycling endurance

Athletes wiil cycle for 5 hours in a row.

Group Type EXPERIMENTAL

maximum effort test on a cycloergometer

Intervention Type OTHER

5 h test on cycloergometer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

maximum effort test on a cycloergometer

5 h test on cycloergometer

Intervention Type OTHER

maximum effort test on a treadmill

5 h test on treadmill

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Specialist in endurance and ultra-endurance. in the 2 disciplines: running and cycling (triathletes, duathletes or trailers achieving at least 30% of their training volume in cycling), and having at least finished one long distance event in the last 2 years,
* Affiliated or beneficiary of a social security scheme.
* Signature of the consent form

Exclusion Criteria

* Any subject who has been injured in the 3 months prior to the protocol
* Anyone with chronic joint pathologies (e.g.: repetitive sprains, patellar or ligament problems).
* Any subject with chronic or central neurological pathologies
* Any subject with a contraindication to magnetic stimulation
* Use of neuro-active substances likely to alter cortico-spinal excitability (hypnotics, antiepileptics, psychotropic drugs, muscle relaxants) on the study.
* Contraindication to the application of a magnetic field:

* Heart or respiratory insufficiency.
* Subject with a cardiac pace maker.
* Cardiac valve wear and serious cardiovascular diseases.
* Presence of prosthetic material or ferromagnetic foreign bodies in the head.
* Presence of cochlear implants or ocular prosthetic material.
* History of neurosurgical interventions.
* Neurological diseases that may affect brain structures and cognitive abilities (e.g., intracranial tumour, multiple sclerosis, history of stroke or traumatic brain injury).
* History of comitiality, contralateral knee disease or musculoskeletal disease.
* Any subject participating at the same time in another interventional experiment requiring physical exercise.
* Any subject who has taken corticosteroids within 3 months (inhalation, infiltration or history of prolonged corticosteroid therapy).
* Any subject under guardianship or curatorship
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Léonard FEASSON, MD PhD

Role: PRINCIPAL_INVESTIGATOR

CHU SAINT-ETIENNE

Guillaume MILLET, PhD

Role: STUDY_DIRECTOR

SAINT-ETIENNE UNIVERSITY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Saint-Etienne

Saint-Etienne, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A01714-35

Identifier Type: OTHER

Identifier Source: secondary_id

19CH217

Identifier Type: -

Identifier Source: org_study_id